Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and infectious disease, and GEDi Cube International Ltd., an AI medical technology company, recently entered a definitive agreement to combine in a stock-for-stock acquisition. “The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an Oct. 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing together two innovative platforms in biotherapeutics and AI, the combined company intends to create comprehensive solutions for early cancer detection, diagnostic insights and effective targeted immunotherapies,” a recent article reads. “According to Dr. Dybul, GEDi Cube and Renovaro Biosciences came together through a shared desire to turbo-charge innovation and efficacy in precision medicine. The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to improve patient outcomes by detecting diseases sooner and matching treatments more precisely based on the individual’s genetic profile.”
To view the full article, visit https://ibn.fm/bPiqr
About Renovaro BioSciences Inc.
Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]